Saudi Chemical subsidiary, Bioventure sign MoU to strengthen strategic relationship

02/02/2023 Argaam
Logo ofAJA Pharmaceutical Industries Ltd. (AJA Pharma)

Logo of AJA Pharmaceutical Industries Ltd. (AJA Pharma)

Saudi Chemical Co. Holding (SCCH) signed on Feb. 1 a memorandum of understanding (MoU), through its pharmaceutical subsidiary AJA Pharmaceutical Industries Ltd. (AJA Pharma), with Bioventure FZ-LLC, a subsidiary of GlobalOne Healthcare Holding.

 

The memorandum was signed in the Saudi Export Development Authority stand during Arab Health Exhibition 2023, the company said in a statement to Tadawul.

 

The MoU was inked to strengthen the existing strategic relationship, with an aim to license and supply new pharmaceutical products in the Middle East region, the statement noted.

 

It is mainly concerned with specialty formulations for nowadays-costly diseases, such as diabetes and tumors.

 

The company indicated that biosimilars are expected to be among the largest and fastest growing therapeutic categories all over the global pharmaceutical sector in the coming years.

 

The financial impact of this MoU will be determined later, the statement said, noting that there are no related parties to this memorandum.

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.